Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Brent Saunders Is Appointed to the BOD of GLO Pharma (Effective Immediately)

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

GLO Pharma, the parent company of breakthrough subtopical skincare brand Ourself, today announces the appointment of Brent Saunders to its Board of Directors. Mr. Saunders, who currently serves as Executive Chairman of The Beauty Health Company, will join the board effective immediately.

Brent Saunders appointment adds a new seat to the GLO Pharma board, which now consists of six members and is led by Chairman Scott L. Glenn.

Brent Saunders is a respected innovator who brings to the Board his extensive leadership experience in the biopharma and medical aesthetics sectors, having led several mergers and acquisitions and served as multiple leadership roles at prominent global pharmaceutical and healthcare companies.

From July 2020 to May 2021, Sauders served as President, Chief Executive Officer and Chair of the Board of Directors of Vesper Healthcare Acquisition Corp. (“Vesper”), and led Vesper’s merger with The HydraFacial Company to become The Beauty Health Company, of which he continues to serve as Executive Chair. Prior, he served as CEO and President of Allergan plc (“Allergan”), best known as the maker of Botox, from July 2014 to May 2020, and was instrumental in leading Allergan’s acquisition by AbbVie, Inc. He also served on Allergan’s board July 2014 to May 2020, and as its Chair from October 2016 to May 2020.

Saunders previously served as Chief Executive Officer and President of Forest Laboratories, Inc. (“Forest”), and later as CEO of pharmaceutical company Actavis, after that company acquired Forest. Later, Saunders negotiated Actavis’ merger with Allergan, which closed at $70.5 billion.

Brent Saunders also held the role of Chief Executive Officer of Bausch + Lomb Incorporated, a leading global eye health company, where he oversaw the company’s acquisition by Valeant Pharmaceuticals in 2013. From 2003 to 2010, he held numerous leadership positions at Schering-Plough Corporation, where he led the company’s merger with Merck & Co. and its acquisition of Organon BioSciences. He is the founder of the SPAC Vesper Healthcare Acquisition, and also currently serves on the boards of directors of BridgeBio Pharma, Inc. and Cisco (NASDAQ: CSCO).

“Mr. Saunders’ experience with scaling and transforming biopharma and medical aesthetics businesses, first with Allergan and now with The Beauty Health Company, makes him an invaluable asset to the GLO Pharma Board,” says Chairman Scott Glenn. “As we build out the product offering of our consumer brand Ourself and a roadmap of topical alternatives to medical procedures, Brent brings incredible insight to the conversation, especially as we develop new innovation in the wrinkle relaxer category in the near future.”

This appointment follows the recent announcement of Rothy’s CFO Dayna Quanbeck to the GLO Pharma Board, and launch of GLO Pharma’s first consumer brand, Ourself, in February 2022. Ourself is backed by $40M in funding to date from investors including Lightspeed Venture Partners, First Round Capital, and Mr. Glenn.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine